The predictability of ASDAS on drug survival in patients with ankylosing spondylitis on biologic therapy: data from the KOBIO registry.

Jinhyun KimMin Jung KimGeun Young OhSun Kyung LeeTaeeun KimTae-Jong Kim

Published in: Therapeutic advances in musculoskeletal disease (2023)

ASDAS-CRP not only has its advantages over BASDAI in assessing disease activity but also low ASDAS-CRP at 1 year can be a marker of long-term drug survival of TNFi therapy.

Keyphrases

ankylosing spondylitis
disease activity
rheumatoid arthritis
systemic lupus erythematosus
rheumatoid arthritis patients
juvenile idiopathic arthritis
stem cells
electronic health record
free survival
adverse drug
drug induced
big data
data analysis